Oncotelic Therapeutics, Inc. Quarterly Preferred Stock, Shares Authorized from Q4 2010 to Q1 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Summary
Oncotelic Therapeutics, Inc. quarterly Preferred Stock, Shares Authorized history and growth rate from Q4 2010 to Q1 2024.
  • Oncotelic Therapeutics, Inc. Preferred Stock, Shares Authorized for the quarter ending March 31, 2024 was 15M shares, unchanged year-over-year.
Preferred Stock, Shares Authorized, Quarterly (shares)
Preferred Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 15M 0 0% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 15M 0 0% Dec 31, 2023 10-Q 2024-05-15
Q1 2023 15M 0 0% Mar 31, 2023 10-Q 2023-05-22
Q4 2022 15M 0 0% Dec 31, 2022 10-Q 2023-05-22
Q3 2022 15M 0 0% Sep 30, 2022 10-Q 2022-11-18
Q2 2022 15M 0 0% Jun 30, 2022 10-Q 2022-08-22
Q1 2022 15M 0 0% Mar 31, 2022 10-Q 2022-05-23
Q4 2021 15M 0 0% Dec 31, 2021 10-K/A 2023-04-20
Q3 2021 15M 0 0% Sep 30, 2021 10-Q 2021-11-22
Q2 2021 15M 0 0% Jun 30, 2021 10-Q 2021-08-20
Q1 2021 15M 0 0% Mar 31, 2021 10-Q 2021-05-24
Q4 2020 15M 0 0% Dec 31, 2020 10-K 2022-04-15
Q3 2020 15M 0 0% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 15M 0 0% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 15M 0 0% Mar 31, 2020 10-Q 2020-06-29
Q4 2019 15M 0 0% Dec 31, 2019 10-K 2021-04-15
Q3 2019 15M 0 0% Sep 30, 2019 10-Q 2019-11-19
Q2 2019 15M 0 0% Jun 30, 2019 10-Q 2019-08-19
Q1 2019 15M 0 0% Mar 31, 2019 10-Q 2019-05-15
Q4 2018 15M 0 0% Dec 31, 2018 10-K 2020-05-14
Q3 2018 15M 0 0% Sep 30, 2018 10-Q 2018-11-14
Q2 2018 15M 0 0% Jun 30, 2018 10-Q 2018-08-14
Q1 2018 15M 0 0% Mar 31, 2018 10-Q 2018-05-14
Q4 2017 15M 0 0% Dec 31, 2017 10-K 2019-04-10
Q3 2017 15M 0 0% Sep 30, 2017 10-Q 2017-11-14
Q2 2017 15M 0 0% Jun 30, 2017 10-Q 2017-08-02
Q1 2017 15M 0 0% Mar 31, 2017 10-Q 2017-05-08
Q4 2016 15M 0 0% Dec 31, 2016 10-K 2018-04-17
Q3 2016 15M 0 0% Sep 30, 2016 10-Q 2016-11-14
Q2 2016 15M 0 0% Jun 30, 2016 10-Q 2016-08-02
Q1 2016 15M 0 0% Mar 31, 2016 10-Q 2016-05-06
Q4 2015 15M 0 0% Dec 31, 2015 10-K 2017-03-30
Q3 2015 15M 0 0% Sep 30, 2015 10-Q 2015-11-12
Q2 2015 15M 0 0% Jun 30, 2015 10-Q 2015-08-06
Q1 2015 15M 0 0% Mar 31, 2015 10-Q 2015-05-07
Q4 2014 15M 0 0% Dec 31, 2014 10-K 2016-03-25
Q3 2014 15M 0 0% Sep 30, 2014 10-Q 2014-11-13
Q2 2014 15M 0 0% Jun 30, 2014 10-Q 2014-08-08
Q1 2014 15M 0 0% Mar 31, 2014 10-Q 2014-05-08
Q4 2013 15M 0 0% Dec 31, 2013 10-K 2015-03-30
Q3 2013 15M 0 0% Sep 30, 2013 10-Q 2013-11-13
Q2 2013 15M 0 0% Jun 30, 2013 10-Q/A 2013-10-18
Q1 2013 15M 0 0% Mar 31, 2013 10-Q 2013-05-09
Q4 2012 15M 0 0% Dec 31, 2012 10-K 2014-03-20
Q3 2012 15M 0 0% Sep 30, 2012 10-Q 2012-11-09
Q2 2012 15M 0 0% Jun 30, 2012 10-Q 2012-08-13
Q1 2012 15M Mar 31, 2012 10-Q 2012-05-11
Q4 2011 15M 0 0% Dec 31, 2011 10-K 2013-03-15
Q3 2011 15M Sep 30, 2011 10-Q 2011-11-10
Q2 2011 15M Jun 30, 2011 10-Q 2011-08-12
Q4 2010 15M Dec 31, 2010 10-K 2012-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.